NasdaqGM:MIRMBiotechs
Mirum Pharmaceuticals (MIRM) Stock Sinks As Losses Deepen Despite Higher Guidance
Mirum Pharmaceuticals came into this earnings season with a bruised stock, down over 26% in the past month, and the selloff accelerated today with an 11% slide to about US$94. Yet the headline from Q2 is not collapse but commercial heft. Net product sales reached US$176.2m and management lifted full year 2026 sales guidance to a range of US$680m to US$700m. The catch sits on the income statement. Mirum reported a quarterly net loss of US$67.2m and basic earnings per share of US$1.06 in the...